Table 2.
Treatments received by participants within the ‘On Treatment’ group
| Last line of treatment | HL | Aggressive B-NHL | Indolent B-NHL | PTCL |
|---|---|---|---|---|
| Chemotherapy | 27 | 0 | 0 | 1 |
| Anti-CD20 alone | 0 | 2 | 27 | 0 |
| Anti-CD20 + chemotherapy | 0 | 36 | 14 | 0 |
| Anti-CD20 + chemotherapy-free agent | 0 | 1 | 6 | 0 |
| Bendamustine | 1 | 2 | 0 | 0 |
| Bendamustine + anti-CD20 | 0 | 0 | 5 | 0 |
| BTK inhibitors | 0 | 0 | 17 | 0 |
| Venetoclax | 0 | 0 | 7 | 0 |
| BTK inhibitor + venetoclax | 0 | 0 | 2 | 0 |
| CAR-T-cell therapy | 0 | 0 | 0 | 0 |
| Autologous stem cell transplant | 0 | 4 | 2 | 0 |
| Allogeneic stem cell transplant | 0 | 0 | 0 | 0 |
| Others |
BV (2), BV + bendamustine (1) |
CPI (1) Bispecific Ab (1) |
Bispecific Ab + lenalidomide (1) |
PI3K inhibitor (1) BV (1) Ciclosporin (1) |
BV, brentuximab vedotin; CP, checkpoint inhibitor; PI3K, phosphatidylinositol 3-kinase